Published in Eur J Neurol on November 12, 2012
Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: a systematic review. J Neurol (2014) 0.85
Expectation modulates the effect of deep brain stimulation on motor and cognitive function in tremor-dominant Parkinson's disease. PLoS One (2013) 0.79
Analysis of nocebo effects of antiepileptic drugs across different conditions. J Neurol (2016) 0.77
Nonspecific adverse events in knee osteoarthritis clinical trials: a systematic review. PLoS One (2014) 0.76
Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation. Neurol Sci (2014) 0.75
Characterization of the adverse events profile of placebo-treated patients in randomized controlled trials on drug-resistant focal epilepsies. J Neurol (2014) 0.75
EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol (2010) 2.53
Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia (1999) 1.81
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord (1998) 1.63
Astrocytoma-like multiple sclerosis. Clin Neurol Neurosurg (2005) 1.38
Animal models of migraine: looking at the component parts of a complex disorder. Eur J Neurosci (2006) 1.16
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol (1999) 1.05
Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease. Hum Genet (1998) 1.00
Guidelines for controlled trials of drugs in tension-type headache: second edition. Cephalalgia (2010) 1.00
Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther (1999) 0.98
Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler (2010) 0.95
Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur J Neurol (2010) 0.92
Investigation of unmedicated early onset restless legs syndrome by voxel-based morphometry, T2 relaxometry, and functional MR imaging during the night-time hours. AJNR Am J Neuroradiol (2011) 0.92
T2 relaxometry and fMRI of the brain in late-onset restless legs syndrome. Neurology (2008) 0.91
Headache in systemic lupus erythematosus: a controlled study. Br J Rheumatol (1998) 0.91
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol (2000) 0.87
Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Nutr Metab Cardiovasc Dis (2007) 0.87
Low RLS prevalence and awareness in central Greece: an epidemiological survey. Eur J Neurol (2007) 0.87
A method for classification of transient events in EEG recordings: application to epilepsy diagnosis. Methods Inf Med (2006) 0.85
Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol (2001) 0.83
CNS siderosis after brachial plexus avulsion. Neurology (2002) 0.83
Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord (2000) 0.82
Acute spontaneous spinal subdural haematomas in a patient with essential thrombocythaemia. J Neurol (2003) 0.80
How should we treat a patient with early Parkinson's disease? Int J Clin Pract (2010) 0.80
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord (2010) 0.80
Akinetic mutism followed by a manic reaction on introduction of steroid replacement for Addison's disease. J Endocrinol Invest (2006) 0.79
Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. Eur J Neurol (2013) 0.78
SUNCT syndrome in the elderly. Cephalalgia (2005) 0.78
Different patterns of rotational behavior in rats after dorsal or ventral striatal lesions with ibotenic acid. Pharmacol Biochem Behav (1988) 0.77
Is migraine really comorbid with systemic lupus erythematosus? Cephalalgia (2004) 0.77
Apraxia related with subcortical lesions due to cerebrovascular disease. Acta Neurol Scand (2009) 0.77
White matter water diffusion changes in primary Sjögren syndrome. AJNR Am J Neuroradiol (2013) 0.77
Add-on topiramate in the treatment of refractory partial-onset epilepsy: clinical experience of outpatient epilepsy clinics from 11 general hospitals. Seizure (2005) 0.76
Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Adv Neurol (2001) 0.76
Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger. Exp Neurol (1998) 0.75
Treatment of motor symptoms in advanced Parkinson's disease: a practical approach. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.75
Two more secondary headaches mimicking chronic paroxysmal hemicrania. Is this the exception or the rule? Headache (1996) 0.75
Attenuation by butalbital of capsaicin-induced c-fos-like immunoreactivity in trigeminal nucleus caudalis. Headache (2001) 0.75
Functional assessment of the rat sciatic nerve following intraoperative expansion: the effect of recovery duration on behavioural, neurophysiological, and morphological measures. Microsurgery (1996) 0.75
Time perception in migraine sufferers: an experimental matched-pairs study. Cephalalgia (2005) 0.75
A negative clinical study in the search for a migraine treatment. Cephalalgia (1997) 0.75
The valproate mechanisms of action in migraine. Cephalalgia (1994) 0.75
Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. J Pharmacol Exp Ther (1997) 0.75